May 20, 2021 02:51 PM EDTUpdated May 21, 01:58 PM

FDA revises and expands draft guidance on adjusting for covariates in RCTs

Zachary Brennan

Senior Editor

The FDA on Thursday revised and expanded a 2019 draft guidance that spells out how to adjust for covariates in the statistical analysis of randomized …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA revises and expands draft guidance on adjusting for covariates in RCTs

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

AstraZeneca, Daiichi’s TROP2 drug misses overall survival goal in Phase 3 breast cancer trial

UK vaccine startup Vicebio snags $100M to take on GSK, Pfizer and Moderna

Ideaya outlines regulatory path for rare eye cancer drug after positive mid-stage data

Regulatory RNA startup CAMP4 files for IPO as more biotechs line up listings

A VC-backed genetic testing startup to 'consider' making an offer to buy 23andMe

PDCs vs. ADCs: A New Frontier in Targeted Cancer Therapies and the Potential for Development Partnerships

FDA re­vis­es and ex­pands draft guid­ance on ad­just­ing for co­vari­ates in RCTs

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

FDA revises and expands draft guidance on adjusting for covariates in RCTs